Peritoneal Surface Oncology Group International (PSOGI)’s Post

Brilliant to have OS benefits in KN-522. Clearly, neoadjuvant IO has revamped our approach in triple negative breast cancer - 34% reduction in mortality is extremely impressive. But with 35% toxicity rates in the IO arm - with potential delays in surgery + long-term toxicities in survivors- and high financial barriers to access, we must rationalise which patients actually need it. Identifying those patients most likely to benefit & those most likely to achieve a pCR would streamline our clinical practice significantly. Look forward to biomarker-adapted data, building on the early data from I-SPY2 etc. Exciting times for TNBC.

#EAU24 is starting on Friday! Tune in for the session on "EAU Guidelines: Artificial Intelligence and new clinical insights" on 7 April at 13:45 and check out the following presentations: 💡OPTIMA Prostate Cancer Care Pathways - Bridging Clinical Practice Guidelines, Real World Evidence and Artificial Intelligence to Enhance Decision-Making 💡Development of Prostate Cancer Typical Case Presentations and Their Usage in OPTIMA’s Guideline Based Decision Support Tool 💡AGREE II Quality Assessment of National and International Clinical Practice Guidelines on Prostate Cancer

🏅 Wednesday Win 🏆 Becker's Healthcare declared that Realyze Intelligence "HIT BIG 💥 in the last two months" sharing that our back-to-back publications in Journal of Clinical Oncology CCI and JAMA Surgery "further validate the company's AI platform as a tool to match cancer patients with clinical trials" ✅ The declaration was part of a celebration of thriving UPMC Enterprises companies -- including our friends at eVisit, Pip Care & BlueSphere Bio. We agree. We've had a BIG year so far... but we're only getting started 🚀 #ClinicalTrialsForAll #NoMoreZombieTrials #ClinicalTrialInnovation #AIinPrecisionOncology #AIOncology #CloseTheCareGap #CancerX #CancerXAccelerator #BeckersMention #RealyzeIntelligence

Today, #EAU24, Europe's biggest urological event is finally is kicking off! Mark this session in your calendars: "EAU Guidelines: Artificial Intelligence and new clinical insights" on 7 April at 13:45 and check out the following presentations: 💡OPTIMA Prostate Cancer Care Pathways - Bridging Clinical Practice Guidelines, Real World Evidence and Artificial Intelligence to Enhance Decision-Making 💡Development of Prostate Cancer Typical Case Presentations and Their Usage in OPTIMA’s Guideline Based Decision Support Tool 💡AGREE II Quality Assessment of National and International Clinical Practice Guidelines on Prostate Cancer

#RESEARCHSPOTLIGHT New PODCAST alert! HIPEC: a narrative review of what HIPEC can do PART-1 https://lnkd.in/d9G_gYwG "The burden of improving survival in patients with peritoneal malignancies is borne by cytoreductive surgery. HIPEC in most situations has a secondary role to play. Yet HIPEC takes the centerstage when it comes to clinical trials, debates and discussion. How did this happen? Or how did we let this happen?" Lana Bijelic, chief, peritoenal malignany unit, CHU Moises Broggi and academic coordinator of European School of Peritoneal Surface Oncology (ESPSO) in conversation with #PaulSugarbaker, secretary general of the PSOGI. ➡ What is the current role of HIPEC in the prevention of PM? ➡ What should be the take home message from the HIPEC T4 trial? ➡ Is peritoneal recurrence free survival a suitable end point for such a trial? It is difficult to put all of Paul Sugarbaker's views on HIPEC and its future into one podcast. ⛔ Will the Spanish Mitomycin C HIPEC trial be a positive trial? Wait for part 2.... Alvaro Arjona-Sánchez Andreas Brandl Santiago González-Moreno, MD, PhD, FACS, FESSO Martin Hübner European Society of Surgical Oncology (ESSO) kurt Van der Speeten

This older girl was treated by our cancer surgeons for a progressive swelling in the right hind limb, with associated neurapraxia and reduced stifle and hip flexion. Her CT showed sciatic nerve and vascular compression from a discrete intermuscular lipoma, along with muscle atrophy. Fast forward 4 days, the mass is gone and the patient is home...more mobile and 1.3kg lighter! Intermuscular lipomas are benign tumours found between muscle bellies, often in the caudal thigh between semimembranosus and semitendinosus as in this patient. After careful excision, the prognosis should be excellent. #AURAVeterinary #canineoncology #surgicaloncology #lipoma

"For me, that ability to navigate there and be so precise is so important" Thanks, Allison DiPasquale MD for her testimonial about "what is important during evaluation". Trust & Embrace #Pintuition, learn more at https://hubs.li/Q02yz9kf0 European Society of Surgical Oncology (ESSO), EUBREAST, AWOgyn, iBRA-NET, iBreastBook Surgitate, TME Breast Care Network, The American Society of Breast Surgeons, #Radiology, #Surgeons, #PatientExperience

During this year’s GCI Trainee Research Day, the Best Presentation on Diagnostics & Therapeutics award went to Dr. Natalie Bjurman and Dr. Bianca Ribeiro de Souza 🎊 Dr. Bjurman is a Medical Resident at UBC OBGYN and has received this award for her presentation on “CRS Score is a Predictor of Successful Interval Debulking Surgery in High Grade Serous Ovarian Cancer.” Dr. Ribeiro de Souza is a Post-Doctoral Fellow at UBC OBGYN. She is receiving this award for her presentation on “Refining prognosis of Endometrioid Ovarian Carcinoma subtypes using hormone receptors expression.” - #gynecologiccancer #gynecancer #traineeresearchday #ovariancancer #endometrialcancer #cancerdiagnostics #cancertherapeutics

The predictors of aggressive recurrence of HCC after resection - Erman Akkus, MD Journal of Hepatology EASL | The Home of Hepatology HPB Surgery #AnkaraUniversity #FacultyOfMedicine #Cancer #HCC #LiverCancer #MedicalOncology #OncoDaily #Oncology #Satellitosis

Neoadjuvant and perioperative #immunotherapy have meaningfully improved event-free survival for patients with resectable #NSCLC, but how much do we know about health-related quality of life (HRQoL)? At #ELCC24, Dr. Jonathan Spicer will present data from the CheckMate 77T study highlighting comprehensive patient-reported outcome data when neoadjuvant immunotherapy is used with chemotherapy prior to surgery followed by adjuvant immunotherapy. #LCSM